An Act to Amend the Laws Governing the Controlled Substances Prescription Monitoring Program
Summary
LD 765 amends Maine’s controlled substances prescription monitoring program, which is the state database used to track dispensing of controlled substances. The bill updates the definition of “prescriber” to expressly include licensed health care professionals and veterinarians who use telehealth to prescribe controlled substances to patients located in Maine, and it adds a definition of “telehealth” by reference to existing law. It also revises reporting requirements for dispensers, including allowing electronic submission or another format approved by the department through a waiver, and it updates the annual reporting deadline for the Department of Health and Human Services from January 15 to April 15.
The bill also repeals a separate statutory section governing the prescription monitoring program and makes conforming changes across several professional licensing statutes so that references to DHHS rules align with the updated controlled substances monitoring framework. In practical terms, the measure modernizes the monitoring program’s administration, accommodates telehealth prescribing, and keeps related licensing provisions consistent with the revised program rules.
Impact
LD 765 changes Title 22 and makes conforming amendments in multiple Title 32 licensing chapters, affecting prescribers, dispensers, veterinarians, and the Department of Health and Human Services. It expands the statutory framework to better account for telehealth-based controlled substance prescribing, adjusts data reporting and submission procedures for prescription monitoring, and removes an obsolete section of law while preserving DHHS authority to implement the program through rulemaking.
Sentiment
No committee transcript or recorded vote information was provided, so the overall sentiment can only be inferred from the bill text. The measure appears largely administrative and modernization-oriented, suggesting a neutral to favorable posture toward updating the prescription monitoring system for telehealth and improving reporting timelines and flexibility. The absence of recorded opposition or debate in the provided materials indicates no documented controversy in the available record.
Contention
The main potential points of contention are the expansion of prescription monitoring rules to telehealth prescribing and the continued reliance on DHHS rulemaking to determine reporting and compliance details. Providers may be attentive to administrative burden, waiver-based reporting, and how telehealth prescribers and veterinarians are treated under the monitoring program. However, no specific objections, amendments, or opposing arguments are included in the provided materials.
Permits patients to indicate that they should not be prescribed opiates and certain other controlled substances in prescription monitoring program information.
Requires prescriptions for animals to be issued in name of animal owner; prohibits unnamed persons from possessing prescribed drugs; and requires Prescription Monitoring Program to include information about controlled substances prescribed by veterinarians.